293 related articles for article (PubMed ID: 28901852)
1. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
3. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
Sun D; Dai M; Shen S; Li C; Yan X
Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
6. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
7. The Role of RASs /RVs in the Current Management of HCV.
Malandris K; Kalopitas G; Theocharidou E; Germanidis G
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
9. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
[TBL] [Abstract][Full Text] [Related]
10. Chemical genetics-based development of small molecules targeting hepatitis C virus.
Jin G; Lee J; Lee K
Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
[TBL] [Abstract][Full Text] [Related]
11. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
Welzel TM; Dultz G; Zeuzem S
J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus NS3 inhibitors: current and future perspectives.
Salam KA; Akimitsu N
Biomed Res Int; 2013; 2013():467869. PubMed ID: 24282816
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
14. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
15. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of fluorene compounds inhibiting HCV variants.
Kim HS; You Y; Mun J; Gadhe CG; Moon H; Lee JS; Pae AN; Kohara M; Keum G; Kim BM; Jang SK
Antiviral Res; 2020 Feb; 174():104678. PubMed ID: 31862501
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies for hepatitis C.
Kim DY; Ahn SH; Han KH
Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
[TBL] [Abstract][Full Text] [Related]
18. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
Pawlotsky JM
Gastroenterology; 2016 Jul; 151(1):70-86. PubMed ID: 27080301
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of NS3 protease inhibitors in HCV infection.
Goudreau N; Llinàs-Brunet M
Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
